The content of this website has been produced in line with the BESPONSA®▼ (inotuzumab ozogamicin) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BESPONSA▼ Prescribing Information for Great Britain click here. BESPONSA▼ Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.
Evaluate VOD Risk
Proactively manage VOD
EBMT diagnostic, prevention and treatment recommendations, please also view the BESPONSA SmPC here
Histologically proven VOD/SOS
Download the guide for Pharmacists for information on dosing, drug interactions, reconstitution, administration, shelf life etc. SmPC should be consulted for full guidance.
Download the Fast Facts PDF document to aid your understanding of BESPONSA. SmPC should be consulted for full guidance.
EBMT, European Society for Blood and Marrow Transplantation; HSCT, haematopoietic stem cell transplantation; SOS, sinusoidal obstruction syndrome; VOD, veno-occlusive disease
Access Support and Resources to read the guidelines or watch videos from leading specialists.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020